**Core Concept**
Acute Myeloid Leukemia (AML) is a heterogeneous group of malignancies characterized by the clonal expansion of myeloid blasts in the bone marrow. The prognosis of AML varies based on specific genetic and molecular characteristics.

**Why the Correct Answer is Right**
The best prognosis in AML is associated with the presence of a normal cytogenetic profile and the absence of unfavorable genetic mutations. In particular, patients with AML who have a normal karyotype and no mutations in the FLT3, NPM1, or CEBPA genes tend to have a favorable response to chemotherapy and a higher chance of achieving complete remission. This is because these patients are more likely to have a lower burden of leukemic cells and a more intact immune system to fight the disease.

**Why Each Wrong Option is Incorrect**
**Option A:** Patients with AML and a complex karyotype have a poorer prognosis due to an increased risk of relapse and a lower chance of achieving complete remission.
**Option B:** While the presence of a FLT3-ITD mutation can be associated with a poorer prognosis, it is not the best indicator of a favorable outcome in AML.
**Option C:** Patients with AML and a high risk of relapse are typically those with unfavorable genetic mutations, such as those involving the MLL gene.

**Clinical Pearl / High-Yield Fact**
When evaluating the prognosis of a patient with AML, it is essential to perform a thorough cytogenetic and molecular analysis to identify any genetic mutations that may impact treatment decisions and outcomes.

**Correct Answer: A. Normal cytogenetic profile and absence of FLT3, NPM1, or CEBPA mutations.**